Bassel Abou-Khalil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bassel Abou-Khalil has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Boulenouar Mesraoua
Neuroscience Institute, Hamad Medical Corporation, Doha, Qatar
4 shared publications - Ali Akabar Asadi-Pooya
Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, USA
3 shared publications - Bernhard Schuknecht
Medical Radiological Institute, 8001 Zurich, Switzerland
2 shared publications - Dorothée Kasteleijn‐Nolst Trenité
Nesmos Department, Faculty of Medicine and Psychology Sapienza University Rome Italy
2 shared publications - Hassan Al Hail
Neuroscience Institute, Hamad Medical Corporation, Doha, Qatar
2 shared publications - Jacqueline A. French
Comprehensive Epilepsy Center New York University Grossman School of Medicine New York New York USA
2 shared publications
Latest Publications
- Open Access
Change in clobazam pharmacokinetics after introduction of cenobamate
Cenobamate is a new antiseizure medication with an unusually high seizure‐free rate, resulting in frequent use in patients with drug‐resistant epilepsy. Many of these patients are taking clobazam (CLB) at baseline. Cenobamate has important interactions with CLB, requiring CLB dose adjustment in conjunction with cenobamate titration. There is limited guidance on the optimal CLB dose adjustment after cenobamate introduction and titration. We measured levels of CLB and its active metabolite N‐desmethylclobazam (N‐CLB) before and after cenobamate titration in 10 subjects with drug‐resistant focal epilepsy. The mean CLB dose at baseline was 34.5 mg/day (range = 15–60 mg/day). We empirically started reducing the dose of CLB when starting 25 mg of cenobamate, then we cut the CLB dose down to 10 or 5 mg when reaching a cenobamate dose of 50 mg daily. The mean final dose of CLB was 9 mg (74% reduction). The average combined CLB + N‐CLB level after cenobamate titration was 2191 μg/mL, not significantly different from baseline (2358 μg/mL). Although there may be individual variability, a 70%–74% CLB dose reduction may be appropriate to achieve an equivalent combined CLB + N‐CLB level.
Open AccessChange in clobazam pharmacokinetics after introduction of cenobamate
Cenobamate is a new antiseizure medication with an unusually high seizure‐free rate, resulting in frequent use in patients with drug‐resistant epilepsy. Many of these patients are taking clobazam (CLB) at baseline. Cenobamate has important interactions with CLB, requiring CLB dose adjustment in conjunction with cenobamate titration. There is limited guidance on the optimal CLB dose adjustment after cenobamate introduction and titration. We measured levels of CLB and its active metabolite N‐desmethylclobazam (N‐CLB) before and after cenobamate titration in 10 subjects with drug‐resistant focal epilepsy. The mean CLB dose at baseline was 34.5 mg/day (range = 15–60 mg/day). We empirically started reducing the dose of CLB when starting 25 mg of cenobamate, then we cut the CLB dose down to 10 or 5 mg when reaching a cenobamate dose of 50 mg daily. The mean final dose of CLB was 9 mg (74% reduction). The average combined CLB + N‐CLB level after cenobamate titration was 2191 μg/mL, not significantly different from baseline (2358 μg/mL). Although there may be individual variability, a 70%–74% CLB dose reduction may be appropriate to achieve an equivalent combined CLB + N‐CLB level.
- 16 March 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 179, 110970
Novel epilepsy treatments in clinical development
- 16 March 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 179, 110970
Novel epilepsy treatments in clinical development
- Open Access
- 24 April 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (5) , 66
Epilepsy Diagnosis When the Routine Ancillary Tests Are Normal
Background/Objectives: In a patient suspected of having epilepsy, routine EEG primarily contributes to the recording of interictal epileptiform discharges (IEDs). Similarly, magnetic resonance imaging (MRI) has become the gold standard imaging technique for identifying epileptogenic structural brain abnormalities. Various EEG and MRI tools to improve epilepsy diagnosis will be presented. Methods: When the initial EEG fails to record IEDs, various EEG measures that can improve EEG performance are presented; a comprehensive epilepsy-targeted MRI protocol to identify, localize, and characterize an epileptogenic lesion will also be described. Results: Studies show that the initial routine EEG fails to record IEDs in approximately 47–50% of epileptic patients. To improve the yield of EEG, subsequent EEG recording should include sleep deprivation, sleep recording, prolonged hyperventilation, optimized light stimulation, addition of an inferior temporal electrode chain, extended EEG duration, and continuous video-EEG monitoring, all measures known to activate IEDs. Furthermore, MRI is interpreted as “normal” in many epilepsy patients, even when performed according to an epilepsy-specific protocol and evaluated by a specialized MRI reader. In such case, the use of the Harmonized Epilepsy Structural Sequence Imaging (HARNESS-MRI) protocol and other imaging tools will improve the detection of potential epileptic lesions, as described in this study. Conclusions: In a patient with a clinical diagnosis of epilepsy but a normal EEG and brain MRI, several options can improve the performance of subsequent EEG and MRI examinations, the subjects of this review.
- 24 April 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (5) , 66
Open AccessEpilepsy Diagnosis When the Routine Ancillary Tests Are Normal
Background/Objectives: In a patient suspected of having epilepsy, routine EEG primarily contributes to the recording of interictal epileptiform discharges (IEDs). Similarly, magnetic resonance imaging (MRI) has become the gold standard imaging technique for identifying epileptogenic structural brain abnormalities. Various EEG and MRI tools to improve epilepsy diagnosis will be presented. Methods: When the initial EEG fails to record IEDs, various EEG measures that can improve EEG performance are presented; a comprehensive epilepsy-targeted MRI protocol to identify, localize, and characterize an epileptogenic lesion will also be described. Results: Studies show that the initial routine EEG fails to record IEDs in approximately 47–50% of epileptic patients. To improve the yield of EEG, subsequent EEG recording should include sleep deprivation, sleep recording, prolonged hyperventilation, optimized light stimulation, addition of an inferior temporal electrode chain, extended EEG duration, and continuous video-EEG monitoring, all measures known to activate IEDs. Furthermore, MRI is interpreted as “normal” in many epilepsy patients, even when performed according to an epilepsy-specific protocol and evaluated by a specialized MRI reader. In such case, the use of the Harmonized Epilepsy Structural Sequence Imaging (HARNESS-MRI) protocol and other imaging tools will improve the detection of potential epileptic lesions, as described in this study. Conclusions: In a patient with a clinical diagnosis of epilepsy but a normal EEG and brain MRI, several options can improve the performance of subsequent EEG and MRI examinations, the subjects of this review.
- Open Access
- 7 March 2025
- Published by MDPI AG in Preprints.org
Epilepsy Diagnosis When the Routine Ancillary Tests Are Normal
Epilepsy is a clinical diagnosis. In a patient suspected of epilepsy, the main contribution of routine EEG is to record interictal epileptiform discharges (IEDs) which include spikes, sharp waves, spike-and-wave discharges, sharp-and-wave discharges, and multiple spike-and-wave discharges. Studies show that the first routine EEG fails to record IEDs in approximately 47–50% of patients with epilepsy. When the clinical history strongly suggests epilepsy, but the first EEG fails to record IEDs, various measures can improve EEG performance, which is the subject of this review. Similarly, in cases of suspected epilepsy, magnetic resonance imaging (MRI) has become the imaging technique of choice to identify structural brain abnormalities. However, in a significant number of cases of clinically suspected epilepsy, MRI is interpreted as “normal” even when performed according to an epilepsy-specific protocol and when evaluated by a specialized MRI reader. In such cases, a comprehensive epilepsy-targeted MRI protocol is the key factor to identify, localize, and characterize an epileptogenic lesion. In this regard, the ILAE Neuroimaging Working Group recommends using the Harmonized Neuroimaging of Epilepsy Structural Sequences (HARNESS-MRI) protocol, among other additional imaging tools, to look for such a lesion; this will be also described in detail below.
- 7 March 2025
- Published by MDPI AG in Preprints.org
Open AccessEpilepsy Diagnosis When the Routine Ancillary Tests Are Normal
Epilepsy is a clinical diagnosis. In a patient suspected of epilepsy, the main contribution of routine EEG is to record interictal epileptiform discharges (IEDs) which include spikes, sharp waves, spike-and-wave discharges, sharp-and-wave discharges, and multiple spike-and-wave discharges. Studies show that the first routine EEG fails to record IEDs in approximately 47–50% of patients with epilepsy. When the clinical history strongly suggests epilepsy, but the first EEG fails to record IEDs, various measures can improve EEG performance, which is the subject of this review. Similarly, in cases of suspected epilepsy, magnetic resonance imaging (MRI) has become the imaging technique of choice to identify structural brain abnormalities. However, in a significant number of cases of clinically suspected epilepsy, MRI is interpreted as “normal” even when performed according to an epilepsy-specific protocol and when evaluated by a specialized MRI reader. In such cases, a comprehensive epilepsy-targeted MRI protocol is the key factor to identify, localize, and characterize an epileptogenic lesion. In this regard, the ILAE Neuroimaging Working Group recommends using the Harmonized Neuroimaging of Epilepsy Structural Sequences (HARNESS-MRI) protocol, among other additional imaging tools, to look for such a lesion; this will be also described in detail below.
- 1 February 2025
- Published by Wolters Kluwer Health in Continuum
- Vol. 31 (1) , 125-164
Update on Antiseizure Medications 2025
OBJECTIVE: This article is an update from the article on antiseizure medication therapy published in the three previous Continuum issues on epilepsy and is intended to cover the vast majority of agents currently available to neurologists in the management of patients with epilepsy. This article addresses antiseizure medications individually, focusing on key pharmacokinetic characteristics, indications, and modes of use. LATEST DEVELOPMENTS: Since the most recent version of this article was published, one new antiseizure medication, ganaxolone, has been approved by the US Food and Drug Administration (FDA), and the indications of some approved medications were expanded. Older antiseizure medications are effective but have tolerability and pharmacokinetic disadvantages. Several newer antiseizure medications have undergone comparative trials demonstrating efficacy equal to and tolerability at least equal to or better than older antiseizure medications as first-line therapy for focal epilepsy. These agents include lamotrigine, oxcarbazepine, levetiracetam, topiramate, zonisamide, and lacosamide. Pregabalin was found to be less effective than lamotrigine. Lacosamide, pregabalin, and eslicarbazepine have undergone successful trials of conversion to monotherapy for focal epilepsy. Other newer antiseizure medications with a variety of mechanisms of action are suitable for adjunctive therapy. ESSENTIAL POINTS: Knowledge of antiseizure medication pharmacokinetics, efficacy, and tolerability profiles facilitates the choice of appropriate antiseizure medication therapy for patients with epilepsy. Rational antiseizure medication combinations should avoid antiseizure medications with unfavorable pharmacokinetic interactions or pharmacodynamic interactions related to mechanism of action.
- 1 February 2025
- Published by Wolters Kluwer Health in Continuum
- Vol. 31 (1) , 125-164
Update on Antiseizure Medications 2025
OBJECTIVE: This article is an update from the article on antiseizure medication therapy published in the three previous Continuum issues on epilepsy and is intended to cover the vast majority of agents currently available to neurologists in the management of patients with epilepsy. This article addresses antiseizure medications individually, focusing on key pharmacokinetic characteristics, indications, and modes of use. LATEST DEVELOPMENTS: Since the most recent version of this article was published, one new antiseizure medication, ganaxolone, has been approved by the US Food and Drug Administration (FDA), and the indications of some approved medications were expanded. Older antiseizure medications are effective but have tolerability and pharmacokinetic disadvantages. Several newer antiseizure medications have undergone comparative trials demonstrating efficacy equal to and tolerability at least equal to or better than older antiseizure medications as first-line therapy for focal epilepsy. These agents include lamotrigine, oxcarbazepine, levetiracetam, topiramate, zonisamide, and lacosamide. Pregabalin was found to be less effective than lamotrigine. Lacosamide, pregabalin, and eslicarbazepine have undergone successful trials of conversion to monotherapy for focal epilepsy. Other newer antiseizure medications with a variety of mechanisms of action are suitable for adjunctive therapy. ESSENTIAL POINTS: Knowledge of antiseizure medication pharmacokinetics, efficacy, and tolerability profiles facilitates the choice of appropriate antiseizure medication therapy for patients with epilepsy. Rational antiseizure medication combinations should avoid antiseizure medications with unfavorable pharmacokinetic interactions or pharmacodynamic interactions related to mechanism of action.
- 23 January 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 164, 110270
Incidence of RINCH in pediatric EMU patients
- 23 January 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 164, 110270
Incidence of RINCH in pediatric EMU patients
- Open Access
- 18 January 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 164, 110241
A multicenter Phase II randomized, placebo-controlled single-blind trial with the SV2A ligand seletracetam in photosensitive epilepsy patients
- 18 January 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 164, 110241
Open AccessA multicenter Phase II randomized, placebo-controlled single-blind trial with the SV2A ligand seletracetam in photosensitive epilepsy patients
- Open Access
- 20 November 2024
- Published by IntechOpen
Epidemiology of Status Epilepticus
The incidence of status epilepticus has varied between studies because of the evolving definition of status epilepticus, variable populations, variable methodology, and improved diagnosis over time. The annual incidence range in early studies was 1.3-27.2 per 100,000. The incidence increased after introduction of diagnostic EEG criteria and an updated definition of status epilepticus. The highest incidence was just over 80 per 100,000 in a prospective Finnish study. The incidence varies with age and is consistently higher in the elderly, as well as in the first year of life. Most studies suggested the incidence to be higher in males. Convulsive is more common than nonconvulsive status epilepticus, but it is likely that the latter is underdiagnosed. While etiology of status epilepticus varies by age, most patients do not have prior epilepsy. Febrile status epilepticus is the most common etiological category in young children, while cerebrovascular disease is the most common in adults.
- 20 November 2024
- Published by IntechOpen
Open AccessEpidemiology of Status Epilepticus
The incidence of status epilepticus has varied between studies because of the evolving definition of status epilepticus, variable populations, variable methodology, and improved diagnosis over time. The annual incidence range in early studies was 1.3-27.2 per 100,000. The incidence increased after introduction of diagnostic EEG criteria and an updated definition of status epilepticus. The highest incidence was just over 80 per 100,000 in a prospective Finnish study. The incidence varies with age and is consistently higher in the elderly, as well as in the first year of life. Most studies suggested the incidence to be higher in males. Convulsive is more common than nonconvulsive status epilepticus, but it is likely that the latter is underdiagnosed. While etiology of status epilepticus varies by age, most patients do not have prior epilepsy. Febrile status epilepticus is the most common etiological category in young children, while cerebrovascular disease is the most common in adults.
- 8 October 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (7) , e209821
The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy
Systematic screening can help identify antiseizure medication (ASM)-associated adverse events (AEs) that may preclude patients from reaching effective doses or completing adequate trial periods. The Adverse Event Profile (AEP) is a self-completed instrument to identify the frequency of common AEs associated with ASM use. This study aimed to compare the AE profile of commonly used ASMs in adults with newly diagnosed focal epilepsy. The Human Epilepsy Project is a prospective, international, observational study investigating markers of treatment response in newly diagnosed focal epilepsy. Participants were enrolled within 4 months of treatment initiation. Adult participants on levetiracetam, lamotrigine, carbamazepine, or oxcarbazepine monotherapy who completed the AEP and Mini International Neuropsychiatric Interview at enrollment were included. Multivariable generalized linear and penalized logistic regression models assessed differences in total and itemized marginal AEP scores and dichotomized responses ("never/rarely" vs "sometimes/always"). A total of 225 adults initiated on levetiracetam (n = 132, 59%), lamotrigine (n = 55, 24%), carbamazepine (n = 19, 8.4%), or oxcarbazepine (n = 19, 8.4%) were included. There were no significant differences in AEP total scores between ASMs. Patients with depression (adjusted marginal score ratio [aMSR] 1.23, 95% CI 1.09-1.39, p = 0.001) and anxiety (aMSR 1.15, 95% CI 1.04-1.26, p = 0.007) had worse AEP total scores than those without. After adjusting for depression and anxiety, levetiracetam users were >3 times more likely to report feelings of aggression (adjusted odds ratio [aOR] 3.38, 95% CI 1.07-10.7, p = 0.038) and almost half as likely to experience unsteadiness (aOR 0.45, 95% CI 0.21-0.99, p = 0.047) than lamotrigine users. Carbamazepine and oxcarbazepine had the highest rates of discontinuation (42.1%, each), followed by levetiracetam (34.8%) and lamotrigine (16.4%). Levetiracetam users had the highest proportion of discontinuations because of AEs alone (18%), and lamotrigine had the lowest (5%). Systematic screening for AEs in adults with newly diagnosed focal epilepsy on ASM monotherapy showed that those with comorbid psychiatric conditions report greater AEs overall, irrespective of ASM. Levetiracetam was associated with >3-fold risk of psychiatric AEs and half the risk of experiencing unsteadiness than lamotrigine. Levetiracetam had the highest proportion of discontinuations because of AEs alone, while lamotrigine had the lowest.
- 8 October 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (7) , e209821
The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy
Systematic screening can help identify antiseizure medication (ASM)-associated adverse events (AEs) that may preclude patients from reaching effective doses or completing adequate trial periods. The Adverse Event Profile (AEP) is a self-completed instrument to identify the frequency of common AEs associated with ASM use. This study aimed to compare the AE profile of commonly used ASMs in adults with newly diagnosed focal epilepsy. The Human Epilepsy Project is a prospective, international, observational study investigating markers of treatment response in newly diagnosed focal epilepsy. Participants were enrolled within 4 months of treatment initiation. Adult participants on levetiracetam, lamotrigine, carbamazepine, or oxcarbazepine monotherapy who completed the AEP and Mini International Neuropsychiatric Interview at enrollment were included. Multivariable generalized linear and penalized logistic regression models assessed differences in total and itemized marginal AEP scores and dichotomized responses ("never/rarely" vs "sometimes/always"). A total of 225 adults initiated on levetiracetam (n = 132, 59%), lamotrigine (n = 55, 24%), carbamazepine (n = 19, 8.4%), or oxcarbazepine (n = 19, 8.4%) were included. There were no significant differences in AEP total scores between ASMs. Patients with depression (adjusted marginal score ratio [aMSR] 1.23, 95% CI 1.09-1.39, p = 0.001) and anxiety (aMSR 1.15, 95% CI 1.04-1.26, p = 0.007) had worse AEP total scores than those without. After adjusting for depression and anxiety, levetiracetam users were >3 times more likely to report feelings of aggression (adjusted odds ratio [aOR] 3.38, 95% CI 1.07-10.7, p = 0.038) and almost half as likely to experience unsteadiness (aOR 0.45, 95% CI 0.21-0.99, p = 0.047) than lamotrigine users. Carbamazepine and oxcarbazepine had the highest rates of discontinuation (42.1%, each), followed by levetiracetam (34.8%) and lamotrigine (16.4%). Levetiracetam users had the highest proportion of discontinuations because of AEs alone (18%), and lamotrigine had the lowest (5%). Systematic screening for AEs in adults with newly diagnosed focal epilepsy on ASM monotherapy showed that those with comorbid psychiatric conditions report greater AEs overall, irrespective of ASM. Levetiracetam was associated with >3-fold risk of psychiatric AEs and half the risk of experiencing unsteadiness than lamotrigine. Levetiracetam had the highest proportion of discontinuations because of AEs alone, while lamotrigine had the lowest.
- Top Cited Papers
- 14 August 2023
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 452, 120766
Drug-resistant epilepsy: Definition, pathophysiology, and management
- 14 August 2023
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 452, 120766
Top Cited PapersDrug-resistant epilepsy: Definition, pathophysiology, and management